The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

uniQure is currently progressing with its pipeline of gene therapies aimed at treating Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, amyotrophic lateral sclerosis (ALS ...

The probability of receiving a pellet was larger in one lateral port (80 vs ... on epileptiform activity and cognitive function in a murine model of mesial temporal lobe epilepsy, prompted by KA ...

Introduction: Pediatric drug-resistant epilepsy (DRE ... seizure onset to the left mesial temporal lobe, specifically the hippocampus, where the hippocampal lead showed significant ictal activity ...

Advances in technology have led to the increasing use of intracranial electrical recording or stimulation in the treatment of conditions such as epilepsy ... such as the medial temporal lobe, where ...